Combination therapies will drive near-doubling of Hodgkin's lymphoma market

9 July 2020

GlobalData expects the Hodgkin’s lymphoma market to grow from $1.2 billion in 2019 to $2.1 billion in 2029 across the eight major markets (8MM) at a moderate compound annual growth rate (CAGR) of 5.5%.

The data and analytics provider’s latest report, Hodgkin’s Lymphoma: Opportunity Analysis and Forecasts to 2029, states that growth will be driven by the anticipated label expansions of Takeda's (TYO: 4502) Adcetris (brentuximab vedotin) and Opdivo (nivolumab), the increased uptake of Keytruda (pembrolizumab) monotherapy in the second and third-line treatment setting, and the emergence of novel therapies.

During the forecast period, the increased use of targeted immunotherapies and novel agents are expected to reduce the dependency on chemotherapies in most treatment settings. The report projects four novel agents to enter the market until 2029.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK